Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Eli Drinkwitz revealed that Mizzou will be without a pair of important players as it tries to finish strong against Virginia ...

Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at ...

Expanding Lilly’s U.S. manufacturing presence in Alabama will boost the Huntsville economy. For every dollar Lilly invests ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Eli Lilly, the maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose weight in a Phase 3 trial, as the company moves closer to submitting the ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

(Editor’s note: This story was written before Eli Manning was not included in the Pro Football Hall of Fame class of 2025.) Two guys are sitting in a bar. They could be talking about who the Giants’ ...

In an interview with PEOPLE, Eli reflects on her Y2K-era pop aesthetic and her forthcoming debut album 'Stage Girl' Ilana Kaplan is a Staff Editor at PEOPLE. She has been working at PEOPLE since 2023.